Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size, Status and Forecast 2020-2026

  • receipt Report ID : 29251
  • calendar_today Published On: Apr, 2020
  • file_copy Pages: 90
  • list Pharmaceuticals and Healthcare

Macular degeneration is a group of eye disease commonly found among children and adults. There are various types of macular degeneration affecting the teens such as Cone-Rod Dystrophy, Best disease, Stargardt disease, Corneal Dystrophy, and Fuch’s Dystrophy.

Asia Pacific is expected to be the fastest growing market owing to the availability of skilled professional such as ophthalmologist, and eye surgeons. Additionally, improving healthcare infrastructure in developing countries like India is further fuelling the growth of juvenile macular degeneration market. China and India contribute to the growth of the market.

In 2020, the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2026, with a CAGR of xx% during 2020-2026.

This report focuses on the global Juvenile Macular Degeneration (Stargardt Disease) Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Juvenile Macular Degeneration (Stargardt Disease) Treatment development in United States, Europe and China.

The key players covered in this study

Sanofi

Bayer

Roche

Pfizer

Allergan

Gilead Sciences

Kubota Pharmaceutical

Alkeus Pharmaceuticals

Astellas Pharma

Ferrer Corporate

Market segment by Type, the product can be split into

Stem Cell Therapy

Gene Therapy

Others

Market segment by Application, split into

Hospitals

Eye Clinics

Others

Market segment by Regions/Countries, this report covers

United States

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Juvenile Macular Degeneration (Stargardt Disease) Treatment status, future forecast, growth opportunity, key market and key players.

To present the Juvenile Macular Degeneration (Stargardt Disease) Treatment development in United States, Europe and China.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Juvenile Macular Degeneration (Stargardt Disease) Treatment are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Report Overview

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered

1.4 Market Analysis by Type

1.4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size Growth Rate by Type (2015-2026)

1.4.2 Stem Cell Therapy

1.4.3 Gene Therapy

1.4.4 Others

1.5 Market by Application

1.5.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Application (2015-2026)

1.5.2 Hospitals

1.5.3 Eye Clinics

1.5.4 Others

1.6 Study Objectives

1.7 Years Considered

2 Global Growth Trends

2.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size

2.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Growth Trends by Regions

2.2.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Regions (2015-2026)

2.2.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Share by Regions (2015-2020)

2.3 Industry Trends

2.3.1 Market Top Trends

2.3.2 Market Drivers

2.3.3 Market Opportunities

3 Market Share by Key Players

3.1 Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Manufacturers

3.1.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue by Manufacturers (2015-2020)

3.1.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Revenue Market Share by Manufacturers (2015-2020)

3.1.3 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Concentration Ratio (CR5 and HHI)

3.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players Head office and Area Served

3.3 Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Product/Solution/Service

3.4 Date of Enter into Juvenile Macular Degeneration (Stargardt Disease) Treatment Market

3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application

4.1 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type (2015-2020)

4.2 Global Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application (2015-2020)

5 United States

5.1 United States Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)

5.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in United States

5.3 United States Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type

5.4 United States Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

6 Europe

6.1 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)

6.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Europe

6.3 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type

6.4 Europe Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

7 China

7.1 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)

7.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in China

7.3 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type

7.4 China Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

8 Japan

8.1 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)

8.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Japan

8.3 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type

8.4 Japan Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

9 Southeast Asia

9.1 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)

9.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Southeast Asia

9.3 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type

9.4 Southeast Asia Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

10 India

10.1 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)

10.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in India

10.3 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type

10.4 India Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

11 Central & South America

11.1 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size (2015-2020)

11.2 Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Players in Central & South America

11.3 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Type

11.4 Central & South America Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Size by Application

12 International Players Profiles

12.1 Sanofi

12.1.1 Sanofi Company Details

12.1.2 Company Description and Business Overview

12.1.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.1.4 Sanofi Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.1.5 Sanofi Recent Development

12.2 Bayer

12.2.1 Bayer Company Details

12.2.2 Company Description and Business Overview

12.2.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.2.4 Bayer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.2.5 Bayer Recent Development

12.3 Roche

12.3.1 Roche Company Details

12.3.2 Company Description and Business Overview

12.3.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.3.4 Roche Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.3.5 Roche Recent Development

12.4 Pfizer

12.4.1 Pfizer Company Details

12.4.2 Company Description and Business Overview

12.4.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.4.4 Pfizer Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.4.5 Pfizer Recent Development

12.5 Allergan

12.5.1 Allergan Company Details

12.5.2 Company Description and Business Overview

12.5.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.5.4 Allergan Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.5.5 Allergan Recent Development

12.6 Gilead Sciences

12.6.1 Gilead Sciences Company Details

12.6.2 Company Description and Business Overview

12.6.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.6.4 Gilead Sciences Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.6.5 Gilead Sciences Recent Development

12.7 Kubota Pharmaceutical

12.7.1 Kubota Pharmaceutical Company Details

12.7.2 Company Description and Business Overview

12.7.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.7.4 Kubota Pharmaceutical Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.7.5 Kubota Pharmaceutical Recent Development

12.8 Alkeus Pharmaceuticals

12.8.1 Alkeus Pharmaceuticals Company Details

12.8.2 Company Description and Business Overview

12.8.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.8.4 Alkeus Pharmaceuticals Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.8.5 Alkeus Pharmaceuticals Recent Development

12.9 Astellas Pharma

12.9.1 Astellas Pharma Company Details

12.9.2 Company Description and Business Overview

12.9.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.9.4 Astellas Pharma Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.9.5 Astellas Pharma Recent Development

12.10 Ferrer Corporate

12.10.1 Ferrer Corporate Company Details

12.10.2 Company Description and Business Overview

12.10.3 Juvenile Macular Degeneration (Stargardt Disease) Treatment Introduction

12.10.4 Ferrer Corporate Revenue in Juvenile Macular Degeneration (Stargardt Disease) Treatment Business (2015-2020)

12.10.5 Ferrer Corporate Recent Development

13 Market Forecast 2019-2025

13.1 Market Size Forecast by Regions

13.2 United States

13.3 Europe

13.4 China

13.5 Japan

13.6 Southeast Asia

13.7 India

13.8 Central & South America

13.9 Market Size Forecast by Product (2019-2025)

13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

12.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Disclaimer

15.3 Author Details

List of Tables and Figures

Table Juvenile Macular Degeneration (Stargardt Disease) Treatment Key Market Segments

Table Key Players Juvenile Macular Degeneration (Stargardt Disease) Treatment Covered